Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 2000

View Archived Issues

Full-year summary: SmithKline Beecham files for FDA approval of three products during 1999

Amrad accelerates development of lead compounds during 1999

Additional mechanism of action revealed for Neovastat

3-D and Boehringer Ingelheim enter R&D collaboration

SangStat presents new antiinflammatory candidate RDP-58

Orphan Medical's Busulfex approved in Israel

Medarex and Regeneron form human antibody drug collaboration

NIH advisory committee approves phase III protocol for Introgen's p53 gene therapy

Collgard receives orphan drug status for scleroderma therapy

Baxter exercises option in cardiovascular collaboration with Sangamo

Small-molecule integrin antagonists under study at Merck & Co.

Novel migraine therapies from Lilly interact with 5-ht1f receptor

Broad-spectrum antibiotics useful for infections due to resistant staphylococci, streptococci

3M's new immunomodulators induce TNF-alpha, IFN-alpha biosynthesis, inhibit Th2 immune response

CCR5 receptor-modulating anilides claimed by SmithKline in recent patent

Continued focus at Lilly on compounds potentiating glutamate receptor function

4-Aminopyridine derivative LI-8 may be clinically useful for antagonizing residual NM block

Swedish authorities issue first approval for next-generation PPI

Sea whip metabolite with potential for the treatment of tuberculosis

Sigma-Tau will develop Zadaxin throughout Europe for HCV and cancer

AstraZeneca's P2T antagonist AR-C69931MX beneficial and safe for acute coronary syndromes

Platelet antiaggregatory activity of antidepressants

NicOx begins clinical trials of HCT-1026 for dermatology indications

Clinical trials of (S)-doxazosin in BPH commenced

ACC news: preliminary clinical results presented for Chiron's rFGF-2 angiogenesis therapy

Novo Nordisk receives approval in Japan for NovoSeven

CholestaGel safe and effective as monotherapy in patients with type IIa hypercholesterolemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 21, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...